Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Abstract

There have been major advances in our knowledge of the contribution of DNA sequence variations to cardiovascular disease and stroke. However, the inner workings of the body reflect the complex interplay of factors beyond the DNA sequence, including epigenetic modifications, RNA transcripts, proteins, and metabolites, which together can be considered the "expressed genome." The emergence of high-throughput technologies, including epigenomics, transcriptomics, proteomics, and metabolomics, is now making it possible to address the contributions of the expressed genome to cardiovascular disorders. This statement describes how the expressed genome can currently and, in the future, potentially be used to diagnose diseases and to predict who will develop diseases such as coronary artery disease, stroke, heart failure, and arrhythmias.

Keywords: AHA Scientific Statements; DNA; cardiovascular diseases; epigenomics; genome; metabolomics; proteomics; stroke.

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles
Feedback